Many countries are exploring the use of ‘vaccine passports’ to enable cross-border travel without quarantine restrictions, to reopen sport and leisure facilities for vaccinated people, or even to work in certain public- or patient-facing roles.

The rapid development of a range of COVID-19 vaccines during the pandemic has renewed interest in public-private partnerships. For example, governments and international agencies have partnered with private pharmaceutical companies to fund research and development programmes.

A proportion of people who contract COVID-19 experience persisting ill health that can have a serious impact on their ability to resume work and social lives.

Following the rapid development of effective COVID-19 vaccines, countries are now facing the challenge of rapidly rolling out vaccination programmes to immunize the population and restore as much of normal life as quickly as possible.

Following the rapid development of effective COVID-19 vaccines, countries are now facing the challenge of rapidly rolling out vaccination programmes to immunize the population and restore as much of normal life as quickly as possible.

While the initial response to the COVID-19 pandemic was focused on preventing and mitigating a public health crisis, the situation has, in many countries, rapidly spiralled into a full blown economic and public finance crisis.

The COVID-19 pandemic has profoundly impacted nearly all countries’ health systems and diminished their capability to provide safe health care, specifically due to errors, harm and delays in diagnosis, treatment and care management.

This webinar will discuss new approaches to measuring national minimum requirements for infection prevention and control and outbreak preparedness, readiness and response.

This workshop is organised by the Austrian National Public Health Institute GÖG and Dutch National Institute for Public Health and the Environment RIVM. Objectives: